Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, discusses the challenges of defining clinically meaningful endpoints in clinical trials for lower- and higher-risk myelodysplastic syndromes (MDS). Prof. Komrokji highlights the evolution of International Working Group (IWG) response criteria, emphasizing the importance of response durability, transfusion independence, overall survival, and quality of life in evaluating treatment benefit. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.